Display options
Cite
Nalwoga A, Cose S, Wakeham K, et al. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop Med Int Health. 2015;20(5):665-672doi: 10.1111/tmi.12464.
Nalwoga, A., Cose, S., Wakeham, K., Miley, W., Ndibazza, J., Drakeley, C., Elliott, A., Whitby, D., & Newton, R. (2015). Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Tropical medicine & international health : TM & IH, 20(5), 665-672. https://doi.org/10.1111/tmi.12464
Nalwoga, Angela, et al. "Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda." Tropical medicine & international health : TM & IH vol. 20,5 (2015): 665-672. doi: https://doi.org/10.1111/tmi.12464
Nalwoga A, Cose S, Wakeham K, Miley W, Ndibazza J, Drakeley C, Elliott A, Whitby D, Newton R. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop Med Int Health. 2015 May;20(5):665-672. doi: 10.1111/tmi.12464. Epub 2015 Feb 09. PMID: 25611008; PMCID: PMC4390463.
Copy Download .nbib Format: NLM
Share it on

Trop Med Int Health. 2015 May;20(5):665-672. doi: 10.1111/tmi.12464. Epub 2015 Feb 09.

Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda.

Tropical medicine & international health : TM & IH

Angela Nalwoga, Stephen Cose, Katie Wakeham, Wendell Miley, Juliet Ndibazza, Christopher Drakeley, Alison Elliott, Denise Whitby, Robert Newton

Affiliations

  1. Medical Research Council/Uganda Virus Research Institute, Entebbe, Uganda.
  2. London School of Hygiene & Tropical Medicine, London, UK.
  3. Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  4. Viral Oncology Section, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  5. University of York, York, UK.
  6. International Agency for Research on Cancer, Lyon, France.

PMID: 25611008 PMCID: PMC4390463 DOI: 10.1111/tmi.12464

Abstract

OBJECTIVE: Unlike other herpes viruses, Kaposi's sarcoma-associated herpes virus (KSHV) is not ubiquitous worldwide and is most prevalent in sub-Saharan Africa. The reasons for this are unclear. As part of a wider investigation of factors that facilitate transmission in Uganda, a high prevalence country, we examined the association between antimalaria antibodies and seropositivity against KSHV.

METHODS: Antibodies against P. falciparum merozoite surface protein (PfMSP)-1, P. falciparum apical membrane antigen (PfAMA)-1 and KSHV antigens (ORF73 and K8.1) were measured in samples from 1164 mothers and 1227 children.

RESULTS: Kaposi's sarcoma-associated herpes virus seroprevalence was 69% among mothers and 15% children. Among mothers, KSHV seroprevalence increased with malaria antibody titres: from 60% to 82% and from 54% to 77%, comparing those with the lowest and highest titres for PfMSP-1 and PfAMA-1, respectively (P < 0.0001). Among children, only antibodies to PfAMA-1 were significantly associated with KSHV seropositivity, (P < 0.0001). In both mothers and children, anti-ORF73 antibodies were more strongly associated with malaria antibodies than anti-K8.1 antibodies.

CONCLUSION: The association between malaria exposure and KSHV seropositivity suggests that malaria is a cofactor for KSHV infection or reactivation.

© 2015 The Authors. Tropical Medicine & International Health published by John Wiley & Sons Ltd.

Keywords: Kaposi's sarcoma-associated herpes virus; Ouganda; Uganda; herpes virus asociado al sarcoma de Kaposi; malaria; paludisme; virus de l'herpès associé au sarcome de Kaposi

References

  1. Nat Rev Microbiol. 2005 Feb;3(2):182-7 - PubMed
  2. Lancet. 2011 Jan 1;377(9759):52-62 - PubMed
  3. J Infect Dis. 2005 Apr 15;191(8):1233-8 - PubMed
  4. Int J Cancer. 2002 Mar 1;98 (1):155-8 - PubMed
  5. PLoS One. 2009 Jun 29;4(6):e6083 - PubMed
  6. Infect Agent Cancer. 2011 Sep 30;6(1):15 - PubMed
  7. J Immunol. 2013 Feb 1;190(3):1038-47 - PubMed
  8. Emerg Infect Dis. 2010 Mar;16(3):392-9 - PubMed
  9. J Infect Dis. 2007 Mar 15;195(6):799-808 - PubMed
  10. PLoS Med. 2010 Jan 19;7(1):e1000218 - PubMed
  11. Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60 - PubMed
  12. J Biol. 2006;5(2):4 - PubMed
  13. Adv Virol. 2011;2011:null - PubMed
  14. Clin Trials. 2007;4(1):42-57 - PubMed
  15. Parassitologia. 1999 Sep;41(1-3):409-14 - PubMed
  16. Curr Opin HIV AIDS. 2012 May;7(3):211-3 - PubMed
  17. AIDS. 2003 Aug 15;17(12):1717-30 - PubMed
  18. Nat Rev Cancer. 2010 Oct;10(10):707-19 - PubMed
  19. J Infect Dis. 2004 Sep 15;190(6):1068-75 - PubMed
  20. Int J Epidemiol. 1999 Oct;28(5):964-74 - PubMed
  21. PLoS Pathog. 2014 Mar 27;10(3):e1004046 - PubMed
  22. Malar J. 2014 Feb 11;13:53 - PubMed
  23. Lancet Oncol. 2009 Apr;10(4):321-2 - PubMed
  24. FEMS Microbiol Immunol. 1991 Aug;3(4):219-27 - PubMed
  25. Clin Vaccine Immunol. 2013 Aug;20(8):1170-80 - PubMed
  26. Curr Opin Oncol. 1998 Sep;10(5):405-12 - PubMed
  27. J Clin Invest. 2010 Dec;120(12):4168-78 - PubMed
  28. PLoS Pathog. 2010 May 20;6(5):e1000912 - PubMed
  29. Nature. 1996 Oct 31;383(6603):787-93 - PubMed
  30. Nature. 1961 Nov 25;192:733-7 - PubMed
  31. PLoS One. 2011;6(9):e25137 - PubMed
  32. Infect Agents Dis. 1996 Oct;5(4):215-22 - PubMed
  33. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):228-33 - PubMed
  34. Infect Immun. 1996 Mar;64(3):744-50 - PubMed
  35. J Infect Dis. 2011 Jul 1;204(1):19-26 - PubMed

Publication Types

Grant support